PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients.

MLA

Yamamoto, Riona, et al. “PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients.” Journal of Clinical Medicine, vol. 13, no. 2, Jan. 2024, p. 510. EBSCOhost, https://doi.org/10.3390/jcm13020510.

APA

Yamamoto, R., Kataoka, N., Imamura, T., Izumida, T., & Kinugawa, K. (2024). PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients. Journal of Clinical Medicine, 13(2), 510. https://doi.org/10.3390/jcm13020510

Chicago

Yamamoto, Riona, Naoya Kataoka, Teruhiko Imamura, Toshihide Izumida, and Koichiro Kinugawa. 2024. “PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients.” Journal of Clinical Medicine 13 (2): 510. doi:10.3390/jcm13020510.